Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - osteoporosis - calcium homeostasis - sondelbay is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).,

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - osteoporosis - calcium homeostasis - qutavina is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - osteoporosis - calcium homeostasis - livogiva is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - teriparatide 250 µg/ml (rhpth(1-34));   - solution for injection - 250 mcg/ml - active: teriparatide 250 µg/ml (rhpth(1-34))   excipient: glacial acetic acid hydrochloric acid mannitol metacresol sodium acetate sodium hydroxide water for injection - forteo, in combination with calcium and vitamin d, is indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture.

Kanada - Kiingereza - Health Canada

avir pharma inc. - teriparatide - solution - 250mcg - teriparatide 250mcg - parathyroid agents

Marekani - Kiingereza - NLM (National Library of Medicine)

novocol pharmaceutical of canada, inc. - teriparatide (unii: 10t9csu89i) (teriparatide - unii:10t9csu89i) - teriparatide injection is indicated. - for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures. - to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. - for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. teriparatide injection is contraindicated in patients with hypersensitivity to teriparatide or to any of its excipients. hypersensitivity reactio

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

eli lilly nederland b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mega lifesciences sdn. bhd. - teriparatide -

Kanada - Kiingereza - Health Canada

eli lilly canada inc - teriparatide - solution - 250mcg - teriparatide 250mcg - parathyroid agents